In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factor-α and transforming growth factor-β genes

Biochemical Pharmacology

Volumn 65, Issue 8, 2003, Pages 1361-1371

  Leiro, José Manuel ^a   Álvarez, Ezequiel ^a   Arranz, Juan Alberto ^a   Siso, Isabel González ^b   Orallo, Francisco ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

Cytokines; Mangiferin; mRNA levels; Nitric oxide; Peritoneal macrophages; Rat; Superoxide anion

Indexed keywords

ALLOPURINOL; DEXAMETHASONE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MANGIFERIN; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; PHORBOL 12 ACETATE 13 MYRISTATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SUPEROXIDE DISMUTASE; THIOGLYCOLIC ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL TONE; CELL STIMULATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MACROPHAGE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; VASCULAR RING;

EID: 0347925017     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00041-8     Document Type: Article

References (71)

1. Young I.S., Woodside J.V. Antioxidants in health and disease. J. Clin. Pathol. 54:2001;176-186.
2. Remacle J., Raes M., Toussaint O., Renard P., Rao G. Low levels of reactive oxygen species as modulators of cell function. Mutat. Res. 316:1995;103-122.
3. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82:2002;47-95.
4. Ramarao N., Gray-Owen S.D., Meyer T.F. Helicobacter pylori induces but survives the extracellular release of oxygen radicals from professional phagocytes using its catalase activity. Mol. Microbiol. 38:2000;103-113.
5. Roebuck K.A. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB [Review]. Int. J. Mol. Med. 4:1999;223-230.
6. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol. Int. 49:1999;91-102.
7. Collins A.R. Oxidative DNA damage, antioxidants, and cancer. Bioessays. 21:1999;238-246.
8. Cuzzocrea S., Riley O.P., Caputi A.P., Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. 53:2001;135-159.
9. Damianaki A., Bakogeorgou E., Kampa M., Notas G., Hatzoglou A., Panagiotou S., Gemetzi C., Kouroumalis E., Martin P.M., Castanas E. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J. Cell Biochem. 78:2000;429-441.
10. Aucamp J., Gaspar A., Hara Y., Apostolides Z. Inhibition of xanthine oxidase by catechins from tea (Camellia sinensis). Anticancer Res. 17:1997;4381-4385.
11. Chung K.T., Wong T.Y., Wei C.I., Huang Y.W., Lin Y. Tannins and human health: a review. Crit. Rev. Food Sci. Nutr. 38:1998;421-464.
12. Zheng M.S., Lu Z.Y. Antiviral effect of mangiferin and isomangiferin on herpes simplex virus. Chin. Med. J. 103:1990;160-165.
13. Guha S., Ghosal S., Chattopadhyay U. Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a naturally occurring glucosylxanthone. Chemotherapy. 42:1996;443-451.
14. Yoosook C., Bunyapraphatsara N., Boonyakiat Y., Kantasuk C. Anti-Herpes simplex virus activities of crude water extracts of Thai medicinal plants. Phytomedicine. 6:2000;411-419.
15. Yoshimi N., Matsunaga K., Katayama M., Yamada Y., Kuno T., Qiao Z., Hara A., Yamahara J., Mori H. The inhibitory effects of mangiferin, a naturally occurring glucosylxanthone, in bowel carcinogenesis of male F344 rats. Cancer Lett. 163:2001;163-170.
16. Ichiki H., Miura T., Kubo M., Ishihara E., Komatsu Y., Tanigawa K., Okada M. New antidiabetic compounds, mangiferin and its glucoside. Biol. Pharm. Bull. 21:1998;1389-1390.
17. Miura T., Ichiki H., Iwamoto N., Kato M., Kubo M., Sasaki H., Okada M., Ishida T., Seino Y., Tanigawa K. Antidiabetic activity of the rhizoma of Anemarrhena asphodeloides and active components, mangiferin and its glucoside. Biol. Pharm. Bull. 24:2001;1009-1011.
18. Miura T., Ichiki H., Hashimoto I., Iwamoto N., Kato M., Kubo M., Ishihara E., Komatsu Y., Okada M., Ishida T., Tanigawa K. Antidiabetic activity of a xanthone compound, mangiferin. Phytomedicine. 8:2001;85-87.
19. Li H., Miyahara T., Tezuka Y., Namba T., Nemoto N., Tonami S., Seto H., Tada T., Kadota S. The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. Biol. Pharm. Bull. 21:1998;1322-1326.
20. Sánchez G.M., Re L., Giuliani A., Núñez-Selles A.J., Davison G.P., León-Fernández O.S. Protective effects of Mangifera indica L. extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. Pharmacol. Res. 42:2000;565-573.
21. Moreira R.R., Carlos I.Z., Vilega W. Release of intermediate reactive hydrogen peroxide by macrophage cells activated by natural products. Biol. Pharm. Bull. 24:2001;201-204.
22. García D., Delgado R., Ubeira F.M., Leiro J. Modulation of rat macrophage function by the Mangifera indica L. extracts Vimang and mangiferin. Int. Immunopharmacol. 2:2002;797-806.
23. Lum H., Roebuck K.A. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. Cell Physiol. 280:2001;C719-C741.
24. López-Farre A., Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension. 38:2001;1400-1405.
25. Leiro J., Iglesias R., Paramá A., Sanmartín M.L., Ubeira F.M. Respiratory burst response of rat macrophages to microsporidian spores. Exp. Parasitol. 98:2001;1-9.
26. Leiro J., Álvarez E., García D., Orallo F. Resveratrol modulates rat macrophage functions. Int. Immunopharmacol. 2:2002;767-774.
27. Orallo F., Álvarez E., Camiña M., Leiro J., Gómez E., Fernández P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol. Pharmacol. 61:2002;294-302.
28. Álvarez E., Leiro J., Orallo F. Effect of (-)-epigallocatechin-3-gallate on respiratory burst of rat macrophages. Int. Immunopharmacol. 2:2002;849-855.
29. Klebe RJ, Grant GM, Grant AM, García MA, Giambernardi TA. RT-PCR without RNA isolation. In: Siebert PD, Larrick JW, editors. Gene cloning and analysis by RT-PCR. Palo Alto, CA: BioTecniques Books; 1998. p. 57-68.
30. Galea E., Reis D.J., Feinstein D.L. Cloning and expression of inducible nitric oxide synthase from rat astrocytes. J. Neurosci. Res. 37:1994;406-414.
31. Zheng J, Ramirez VD. Isolation of a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA isoform from rat brain by a rapid PCR-based cloning method and its expression by RT-PCR. National Center for Biotechnology Information (NCBI), accession number AF106860; 2000.
32. Leiro J., Siso M.I.G., Paramá A., Ubeira F.M., Sanmartín M.L. RFLP analysis of PCR-amplified small subunit ribosomal DNA of three fish microsporidian species. Parasitology. 120:2000;113-119.
33. Dostal DE, Kempinski AM, Motel TJ, Baker KM. Absolute quantification of messenger RNA using multiplex RT-PCR. In: Siebert PD, Larrick JW, editors. Gene cloning and analysis by RT-PCR. Natick, MA: BioTechniques Books; 1998, p. 71-90.
34. Orallo F. Study of the in vivo and in vitro cardiovascular effects of a hydralazine-like vasodilator agent (HPS-10) in normotensive rats. Br. J. Pharmacol. 121:1997;1627-1636.
35. Holland H.L., Gu J.X., Orallo F., Camiña M., Fabeiro P. Enantioselective synthesis and pharmacological evaluation of a new type of verapamil analog with hypotensive and calcium antagonist activities. Pharmaceut. Res. 16:1999;281-287.
36. Darley-Usmar V., Wiseman H., Halliwell B. Nitric oxide and oxygen radicals: a question of balance. FEBS Lett. 369:1995;131-135.
37. Bubarkt V, Kolb H. Nitric oxide in the immunopathogenesis of type 1 diabetes. In: Mayer B, editor. Handbook of experimental pharmacology, Vol. 143. Nitric oxide. Berlin: Springer; 2000. p. 525-44.
38. Kaul A., Khanduja K.L. Plant polyphenols inhibit benzoyl peroxide-induced superoxide anion radical production and diacylglyceride formation in murine peritoneal macrophages. Nutr. Cancer Int. J. 35:1999;207-211.
39. Forman H.J., Torres M. Signaling by the respiratory burst in macrophages. IUBMB Life. 51:2001a;365-371.
40. Forman H.J., Torres M. Redox signaling in macrophages. Mol. Aspects Med. 22:2001;189-216.
41. Nathan C., Xie Q.W. Nitric oxide synthase: roles, tolls and control. Cell. 78:1994;915-918.
42. Mendes A.F., Carvalho A.P., Caramona M.M., Lopes M.C. Diphenyleneiodonium inhibits NF-kappaB activation and iNOS expression induced by IL-1beta: involvement of reactive oxygen species. Mediators Inflamm. 10:2001;209-215.
43. Kleinert H., Euchenhofer C., Ihrig-Biedert I., Forstermann U. In murine 3T3 fibroblasts, different second messenger pathways resulting in the induction of NO synthase II (iNOS) converge in the activation of transcription factor NF-kappaB. J. Biol. Chem. 271:1996;6039-6044.
44. Lin Y.L., Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol. Pharmacol. 52:1997;465-472.
45. Virgili F., Kobuchi H., Packer L. Procyanidins extracted from Pinus maritima (Pycnogenol): scavengers of free radical species and modulators of nitrogen monoxide metabolism in activated murine RAW264.7 macrophages. Free Radic. Biol. Med. 24:1998;1120-1129.
46. Xiong O., Tezuka Y., Kaneko T., Li H., Tran L.Q., Hase K., Namba T., Kadota S. Inhibition of nitric oxide by phenylethanoids in activated macrophages. Eur. J. Pharmacol. 14:2000;137-144.
47. Chen Y., Yang L T.J. Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation. Biochem. Pharmacol. 59:2000;1445-1457.
48. Luceri C., Caderni G., Sanna A., Dolara P. Red wine and black tea polyphenols modulate the expression of cycloxygenase-2, inducible nitric oxide synthase and glutathione-related enzymes in azoxymethane-induced f344 rat colon tumors. J. Nutr. 132:2002;1376-1379.
49. Tsai S.-H., Lin-Shiau S.-Y., Lin J.-K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br. J. Pharmacol. 126:1999;673-680.
50. Förstermann U. Regulation of nitric oxide synthase expression and activity. In: Mayer B, editor. Handbook of experimental pharmacology, Vol. 143. Nitric oxide. Berlin: Springer; 2000. p. 71-91.
51. Suganuma M., Sueoka E., Sueoka N., Okabe S., Fujiki H. Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-alpha expression. Biofactors. 13:2000;67-72.
52. Yang F., Oz H.S., Barve S., de Villiers W.J., McClain C.J., Varilek G.W. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol. Pharmacol. 60:2001;528-533.
53. Ding A., Nathan C.F., Graycar J., Derynck R., Stuehr D.J., Srimal S. Macrophage deactivating factor and transforming growth factors β1, β2 and β3 inhibit catalytic activity. Neuropharmacology. 33:1990;1245-1251.
54. Förstermann U., Schmidt H.H., Kohlhaas K.L., Murad F. Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-beta. Eur. J. Pharmacol. 225:1992;161-165.
55. Schini V.B., Durante W., Elizondo E., Scott B.T., Junquero D.C., Schafer A.I., Vanhoutte P.M. The induction of nitric oxide synthase activity is inhibited by TGF-beta1, PDGFAB and PDGFBB in vascular smooth muscle cells. Eur. J. Pharmacol. 216:1992;379-383.
56. Perrella M.A., Yoshizumi M., Fen Z., Tsai J.-C., Hsieh C.-M., Kourembanas S., Lee M.-E. Transforming growth factor-β1, but not dexamethasone, down-regulates nitric oxide synthase mRNA after its induction by interleukin-1β in rat smooth muscle cells. J. Biol. Chem. 269:1994;14595-14600.
57. Vodovotz Y. Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease. Nitric Oxide. 1:1997;3-17.
58. Miyajima A., Chen J., Kirman I., Poppas D.P., Darracott-Vaughan E.J.R., Felsen D. Interaction of nitric oxide and transforming growth factor-beta1 induced by angiotensin II and mechanical stretch in rat renal tubular epithelial cells. J. Urol. 164:2000;1729-1734.
59. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-β Nature. 334:1988;260-262.
60. Vodovotz Y., Bogdan C., Paik J., Xie Q.W., Nathan C.F. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178:1993;605-613.
61. Markowitz S.D., Roberts A.B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 7:1996;93-102.
62. McCaffrey T.A., Du B., Consigli S., Szabo P., Bray P.J., Hartner L., Weksler B.B., Sanborn T.A., Bergman G., Bush H.L. Jr. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J. Clin. Invest. 100:1997;2182-2188.
63. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., Roberts A.B., Sporn M.B., Ward J.M., Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U.S.A. 90:1993;770-774.
64. Batuman O., Go D., Clark L.T., Smith E.L., Clements P., Feit A., Lederer D. Relationship between cytokine levels and coronary artery disease in women. Heart Dis. 3:2001;80-84.
65. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:2000;840-844.
66. Carr A., Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic. Biol. Med. 28:2000;1806-1814.
67. Depeint F., Gee J.M., Williamson G., Johnson I.T. Evidence for consistent patterns between flavonoid structures and cellular activities. Proc. Nutr. Soc. 61:2002;97-103.
68. Somers M.J., Harrison D.G. Reactive oxygen species and the control of vasomotor tone. Curr. Hypertens. Rep. 1:1999;102-108.
69. Munzel T., Hink U., Heitzer T., Meinertz T. Role for NADPH/NADH oxidase in the modulation of vascular tone. Ann. NY Acad. Sci. 874:1999;386-400.
70. Britten M.B., Zeiher A.M., Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J. Int. Med. 245:1999;315-327.
71. Mandriota S.J., Menoud P.-A., Peppers M.S. Transforming growth factor β1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J. Biol. Chem. 271:1996;11500-11505.